Evidence map›Paper›PMID 21733225›Full record

ArticleThe international journal of neuropsychopharmacology2012

Distinct periods of developmental sensitivity to the effects of 3,4-(±)-methylenedioxymethamphetamine (MDMA) on behaviour and monoamines in rats.

Matthew R Skelton, Devon L Graham, Tori L Schaefer, Curtis E Grace, Amanda A Braun, Lindsey N Burns, Robyn M Amos-Kroohs, Michael T Williams, Charles V Vorhees

Open access · bronzeAbstract read
In one paragraph

Article in The international journal of neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Matthew R SkeltonDivision of Neurology, Cincinnati Children's Research Foundation and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Devon L Graham
Tori L Schaefer
Curtis E Grace
Amanda A Braun
Lindsey N Burns
Robyn M Amos-Kroohs
Michael T Williams
Charles V Vorhees
University of Cincinnati Medical Center · USCincinnati Children's Hospital Medical Center · US

Funding

TRAINING PROGRAM IN TERATOLOGYT32ES007051 · NIEHS · CINCINNATI CHILDRENS HOSP MED CTR · PI VORHEES, CHARLES V · 1985 to 2018
$4.1M
Effects of Neonatal MDMA on Brain and BehaviorR01DA021394 · NIDA · CINCINNATI CHILDRENS HOSP MED CTR · PI VORHEES, CHARLES V · 2006 to 2010
$1.4M
NIDA NIH HHS DA021394NIDA NIH HHS R01 DA021394NIEHS NIH HHS T32 ES007051
6 · The paper itself

Abstract

Previous findings showed allocentric and egocentric learning deficits in rats after MDMA treatment from postnatal days (PD) 11-20 but not after treatment from PD 1-10. Shorter treatment periods (PD 1-5, 6-10, 11-15, or 16-20) resulted in allocentric learning deficits averaged across intervals but not for any interval individually and no egocentric learning deficits individually or collectively. Whether this difference was attributable to treatment length or age at the start of treatment was unclear. In the present experiment rat litters were treated on PD 1-10, 6-15, or 11-20 with 0, 10, or 15 mg/kg MDMA q.i.d. at 2-h intervals. Two male/female pairs/litter received each treatment. One pair/litter received acoustic startle with prepulse inhibition, straight channel swimming, Cincinnati water maze (CWM), and conditioned fear in a latent inhibition paradigm. The other pair/litter received locomotor activity, straight channel swimming, Morris water maze (MWM), and locomotor activity retest with MK-801 challenge. MDMA impaired CWM learning following PD 6-15 or 11-20 exposure. In MWM acquisition, all MDMA-treated groups showed impairment. During reversal and shift, the PD 6-15 and PD 11-20 MDMA-treated groups were significantly impaired. Reductions in locomotor activity were most evident after PD 6-15 treatment while increases in acoustic startle were most evident after PD 1-10 treatment. After MK-801 challenge, MDMA-treated offspring showed less locomotion compared to controls. Region-specific changes in brain monoamines were also observed but were not significantly correlated with behavioural changes. The results show that PD 11-20 exposure to MDMA caused the largest long-term cognitive deficits followed by PD 6-15 exposure with PD 1-10 exposure least affected. Other effects, such as those upon MK-801-stimulated locomotion showed greatest effects after PD 1-10 MDMA exposure. Hence, each effect has a different window of developmental susceptibility.

Indexed as

Acoustic StimulationAgingAnimalsAnimals, NewbornBehavior, AnimalBiogenic MonoaminesBody WeightConditioning, PsychologicalDizocilpine MaleateDose-Response Relationship, DrugExcitatory Amino Acid AntagonistsFearFemaleHallucinogensInhibition, PsychologicalMaleBiogenic MonoaminesDizocilpine MaleateExcitatory Amino Acid AntagonistsHallucinogensN-Methyl-3,4-methylenedioxyamphetamine

Identifiers

PMID21733225
PMCPMC4599583
OpenAlexW2081328013

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.